Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]
Discontinued
Reference number: GID-TA10906
The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer ID4006. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal.
Following an update from the company that market the drug, NICE will not be progressing with the scoping exercise at this stage. The consultation on the draft scope will now close. Please accept our apologies for any inconvenience.